A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

A case of immune checkpoint inhibitor-associated myocarditis after initiation of atezolizumab plus bevacizumab therapy for advanced hepatocellular carcinoma

Published:2021-05-23 Issue: Volume: Page:
ISSN:1865-7257
Container-title:Clinical Journal of Gastroenterology
language:en
Short-container-title:Clin J Gastroenterol

Author:

Iwasaki Shuichiro,Hidaka Hisashi^ORCID,Uojima Haruki,Hashimura Miho,Nabeta Takeru,Sanoyama Itaru,Wada Naohisa,Kubota Kousuke,Nakazawa Takahide,Shibuya Akitaka,Koizumi Wasaburo

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12328-021-01442-2.pdf

Reference14 articles.

1. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. IMbrave150 Investigators. N Engl J Med. 2020;382:1894–905.

2. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158–68.

3. Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749–55.

4. Patient Care Guide for first-line HCC | TECENTRIQ (atezolizumab) (tecentriq-hcp.com)

5. Moslehi JJ, Salem JE, Sosman JA, et al. Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis. Lancet. 2018;391:933.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Interleukin-7 Risk Allele, Lymphocyte Counts, and Autoantibodies for Prediction of Risk of Immune-Related Adverse Events in Patients Receiving Atezolizumab plus Bevacizumab Therapy for Unresectable Hepatocellular Carcinoma;Oncology;2024-07-30

2. Immune Checkpoint Inhibitor-Associated Myocarditis: A Literature Review;Cureus;2024-01-25

3. Systemic therapies in hepatocellular carcinoma: A revolution?;United European Gastroenterology Journal;2024-01-24

4. Significance of the autoantibody assay in predicting the development of immune‐related adverse events in patients receiving atezolizumab plus bevacizumab combination therapy for unresectable hepatocellular carcinoma;Hepatology Research;2023-10-06

5. Association Between Immune-Related Adverse Events and Survival in Patients with Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab;The Oncologist;2023-04-06